Insights That Move You Forward

Helping you make smarter decisions, avoid costly missteps, & bring safe, effective products to market with confidence

The Sales Trap That’s Costing You Clients: Q&A with Michael Nilo on The Business of Learning Podcast
Regulatory Strategy, Industry Commentary, Podcast Features, Business & Growth, Consulting & Advisory, Client Relationships, Clinical & Quality Integration Crystal Norwood Regulatory Strategy, Industry Commentary, Podcast Features, Business & Growth, Consulting & Advisory, Client Relationships, Clinical & Quality Integration Crystal Norwood

The Sales Trap That’s Costing You Clients: Q&A with Michael Nilo on The Business of Learning Podcast

In this Q&A recap of The Business of Learning Podcast, NMCG President & Principal Consultant Michael Nilo joins host João Camargo to unpack the “sales trap” that costs expert service providers clients: stopping at “you can’t do that” instead of mapping what is possible. Learn how NMCG blends regulatory rigor with practical, business-savvy guidance for medtech innovators.

Read More
The Growing Role of Real-World Evidence in Regulatory Decisions
Regulatory Strategy, Clinical Research, Post-Market Surveillance, Real-World Evidence Crystal Norwood Regulatory Strategy, Clinical Research, Post-Market Surveillance, Real-World Evidence Crystal Norwood

The Growing Role of Real-World Evidence in Regulatory Decisions

Real-world evidence (RWE) is reshaping regulatory decisions, supplementing clinical trial data with insights from EHRs, registries, and digital tools. Regulators now rely on RWE to strengthen approvals and post-market surveillance. See how NMCG helps sponsors design data strategies that anticipate this evolving landscape. 

Read More
MedTech Regulatory Risk: Navigating the FDA During a Government Shutdown
Regulatory Strategy, FDA Insights, Risk Mitigation, Industry Commentary, Podcast Features Crystal Norwood Regulatory Strategy, FDA Insights, Risk Mitigation, Industry Commentary, Podcast Features Crystal Norwood

MedTech Regulatory Risk: Navigating the FDA During a Government Shutdown

When the U.S. government shuts down, FDA operations slow—and medical device companies can face costly delays. In this Global Medical Device Podcast Q&A, NMCG President and former FDA Scientific Reviewer Michael Nilo explains what continues, what stops, and how MedTech leaders can strategically navigate the disruption.

Read More